Coating composition suitable for pharmaceutical or nutraceutical dosage forms

Patent metadata

Field	Value
Publication number	US-9844511-B2
Application number	US-201114118078-A
Country	US
Kind code	B2
Filing date	Jun 17, 2011
Priority date	Jun 17, 2011
Publication date	Dec 19, 2017
Grant date	Dec 19, 2017

Abstract

The invention relates to a coating composition suitable for the coating of a pharmaceutical or nutraceutical dosage form, comprising a core comprising one or more pharmaceutical or nutraceutical active ingredients, wherein the coating composition is comprising at least 20% by weight of an enteric core/shell polymer composition derived from an emulsion polymerization process, wherein either the core of the core/shell polymer composition is formed by a water-insoluble, not cross-linked polymer or copolymer and the shell of the core/shell polymer composition is formed by an anionic polymer or copolymer or vice versa.

First claim

The invention claimed is:

1. A coating composition consisting essentially of components suitable for the coating a pharmaceutical or nutraceutical dosage form, comprising:
at least 20% by weight of an enteric core/shell polymer composition derived from an emulsion polymerization process whereby (1) core polymer particles are formed by monomer polymerization in an emulsion, and (2) the shell is polymerized onto the core polymer particles by subsequent monomer polymerization in the same emulsion,
wherein the enteric core/shell polymer composition has an homogeneous microstructure without visible phase separation; and
wherein either the core polymer of the core/shell polymer composition is a water-insoluble, not cross-linked polymer or copolymer and the shell polymer of the core/shell polymer composition is an anionic polymer or copolymer, or the shell polymer of the core/shell polymer composition is a water-insoluble, not cross-linked polymer or copolymer and the core polymer of the core/shell polymer composition is an anionic polymer or copolymer.

2. The coating composition according to claim 1 , further comprising up to 80% by weight of at least one pharmaceutical or nutraceutical excipient selected from the group consisting of an antioxidant, a brightener, a binding agent, a flavouring agent, a flow aid, a fragrance, a glidant, a penetration-promoting agent, a pigment, a plasticizer, a polymer, a pore-forming agent and a stabilizer.

3. The coating composition according to claim 1 , wherein the composition is present in the form of a solid phase of an aqueous dispersion with a solid content of from 1 to 60% by weight.

4. The coating composition according to claim 1 , wherein the composition is present in the form of a dry powder or a granulate.

5. The coating composition according to claim 1 , wherein the water-insoluble polymer or copolymer is selected from the group consisting of (meth)acrylate polymer, (meth)acrylate copolymer, polyvinyl polymer, polyvinyl copolymer, and cellulose having not more than 12% by weight of monomer residues with an ionic functional group.

6. The coating composition according to claim 1 , wherein the anionic polymer or copolymer is selected from the group consisting of (meth)acrylate polymer, (meth)acrylate copolymer having from 5 to 75% by weight of monomeric residues with an anionic functional group, polyvinyl polymer, polyvinyl copolymer, and cellulose.

7. The coating composition according to claim 1 , wherein the coating composition comprises a pharmaceutical or nutraceutical active ingredient, and the composition is suitable for coating a pharmaceutical or nutraceutical dosage form.

8. A gastric resistant pharmaceutical or nutraceutical dosage form, comprising:
a core comprising a pharmaceutical or nutraceutical active ingredient; and
a gastric resistant coating layer coating the core,
wherein the gastric resistant coating layer is the coating composition according to claim 1 ,
wherein a release of the pharmaceutical or nutraceutical active ingredient is not more than 10% under in-vitro conditions at pH 1.2 after 2 hours in medium according to USP with and without the addition of 20% (v/v) ethanol, and
wherein a release of the pharmaceutical or nutraceutical active ingredient is at least 50% under in-vitro conditions at pH 6.8 or pH 7.2 after 45 minutes in a buffered medium according to USP.

9. The dosage form according to claim 8 , wherein a release of the pharmaceutical or nutraceutical active ingredient is not more than 5% under in-vitro conditions at pH 1.2 after 2 hours in medium according to USP with and without the addition of 20% (v/v) ethanol.

10. The dosage form according to claim 8 , wherein a release of the pharmaceutical or nutraceutical active ingredient is at least 80% under in-vitro conditions at pH 6.8 or pH 7.2 after 45 minutes in a buffered medium according to USP.

11. The coating composition according to claim 1 , applied to a core comprising a pharmaceutical or nutraceutical active ingredient to form a pharmaceutical or nutraceutical dosage form, wherein a resulting pharmaceutical or nutraceutical dosage form shows a release of the pharmaceutical or nutraceutical active ingredient of not more than 10% under in-vitro conditions at pH 1.2 after 2 hours in medium according to USP with and without the addition of 20% (v/v) ethanol.

12. The coating composition according to claim 1 , wherein the composition is suitable as a binding agent for binding of a pharmaceutical or nutraceutical active ingredient in a coating or as a matrix former in the core of a pharmaceutical or nutraceutical dosage form.

13. A core/shell polymer composition consisting essentially of components suitable for the coating a pharmaceutical or nutraceutical dosage form,
wherein the core/shell polymer composition is derived from an emulsion polymerization process whereby (1) core polymer particles are formed by monomer polymerization in an emulsion, and (2) the shell is polymerized onto the core polymer particles by subsequent monomer polymerization in the same emulsion;
wherein the core/shell polymer composition has an homogeneous microstructure without visible phase separation; and
wherein either the core polymer of the core/shell polymer composition is a water-insoluble, not cross-linked polymer or copolymer and the shell polymer of the core/shell polymer composition is an anionic polymer or copolymer, or the shell polymer of the core/shell polymer composition is a water-insoluble, not cross-linked polymer or copolymer and the core polymer of the core/shell polymer composition is an anionic polymer or copolymer.

14. The core/shell polymer composition according to claim 13 , wherein a weight of the core polymer is from 10 to 95% of a weight of the total composition.

15. The core/shell polymer composition according to claim 13 , wherein the core polymer of the core/shell polymer composition is formed by a water-insoluble, not cross-linked polymer or copolymer and the shell polymer of the core/shell polymer composition is formed by an anionic polymer or copolymer.

16. The core/shell polymer composition according to claim 13 , wherein the shell polymer of the core/shell polymer composition is formed by a water-insoluble, not cross-linked polymer or copolymer and the core polymer of the core/shell polymer composition is formed by an anionic polymer or copolymer.

17. The core/shell polymer composition according to claim 13 , wherein the core/shell polymer composition is obtained by an emulsion polymerization process in the same emulsion.

18. The coating composition according to claim 1 , wherein the core polymer of the core/shell polymer composition is a water-insoluble, not cross-linked polymer or copolymer and the shell polymer of the core/shell polymer composition is an anionic polymer or copolymer.

19. The coating composition according to claim 1 , wherein the water-insoluble polymer or copolymer is selected from the group consisting of (meth)acrylate polymer, (meth)acrylate copolymer, polyvinyl polymer, polyvinyl copolymer, and cellulose having not more than 12% by weight of monomer residues with an ionic functional group and the anionic polymer or copolymer is selected from the group consisting of (meth)acrylate polymer, (meth)acrylate copolymer having 5-75% by weight of monomer residues with an anionic functional group, polyvinyl polymer, polyvinyl copolymer, and cellulose.

20. The core/shell polymer composition according to claim 13 , wherein the water-insoluble polymer or copolymer is selected

Assignees

• Nollenberger Kathrin
• Schattka Jan Hendrik
• Leubert Rene
• Hermes Florian
• Assmus Manfred
• Meier Christian
• Dassinger Thomas
• Riermeier Thomas
• Evonik Roehm Gmbh

Inventors

• Nollenberger Kathrin
• Schattka Jan Hendrik
• Leubert Rene
• Hermes Florian
• Assmus Manfred
• Meier Christian
• Dassinger Thomas
• Riermeier Thomas

Classifications

• A61K9/5026 Primary

  obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates · CPC title

• A61K9/2886 Primary

  having two or more different drug-free coatings; Tablets of the type inert core-drug layer-inactive layer (of the type active core-drug layer-inactive layer A61K9/209) · CPC title

• A61K47/32

  Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers {, poly(meth)acrylates, or polyvinyl pyrrolidone} · CPC title

• C08F2/22

  Emulsion polymerisation · CPC title

• C08F265/06

  Polymerisation of acrylate or methacrylate esters on to polymers thereof · CPC title